This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
by Kinjel Shah
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
by Sundeep Ganoria
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
5 Must-See Stocks with Perfect Earnings Charts
by Tracey Ryniec
These 5 companies have not missed on earnings in 5 years. That's an impressive feat with the pandemic hitting in 2020.
Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
AbbVie (ABBV) Stock Moves -0.22%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $170.30 in the latest trading session, marking a -0.22% move from the prior day.
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
by Kinjel Shah
J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
by Zacks Equity Research
Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and immunology indications.
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
by Kinjel Shah
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Why the Market Dipped But AbbVie (ABBV) Gained Today
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
by Zacks Equity Research
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
The Zacks Analyst Blog Highlights Visa, AbbVie, Analog Devices and Precipio
by Zacks Equity Research
Visa, AbbVie, Analog Devices and Precipio are included in this Analyst Blog.
Top Research Reports for Visa, AbbVie & Analog Devices
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Analog Devices, Inc. (ADI), as well as a micro-cap stock Precipio, Inc. (PRPO).
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
AbbVie (ABBV) Stock Moves -0.32%: What You Should Know
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day.
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
by Kinjel Shah
SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
by Zacks Equity Research
ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?
by Kinjel Shah
Investors may stay invested in PFE stock to see how its new growth drivers perform
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
by Zacks Equity Research
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.